Researchers at MIT have found that “more than 98% of prisons in the United States experienced at least ten days that were hotter than every previous summer, with the worst of the heat-exposed prisons concentrated in the Southwest,” reports Minnah Arshad for USA Today. s
MIT researchers developed a new method to model how climate change will impact the number of “outdoor days” and found that Southern states in the U.S. will lose a significant number of outdoor days, reports Kristin Toussaint for Fast Company. Prof. Elfatih Eltahir explains that the concept of outdoor days is, “an attempt for me to bring the issue of climate change home. When someone tells you global temperatures are going to increase by 3 degrees, that’s one thing. If someone tells you that your outdoor days will be dropping by 20% or 30%, that’s another thing.”
A new commentary by Prof. Jonathan Gruber and his colleagues outlines a proposal for a new long-term care at home plan, aimed at enabling seniors to stay in their homes, reports Jonathan Cohn for HuffPost. “Relative to other countries, we’re very nursing home focused, and we’re not really doing enough to keep people at home,” says Gruber. “I also just think it’s a valuable benefit to people that makes their lives better.”
Writing for Forbes, Senior Lecturer Guadalupe Hayes-Mota '08 MS '16, MBA '16 explores the challenges, opportunities and future of AI-driven drug development. “I see the opportunities for AI in drug development as vast and transformative,”
New Yorker reporter Dhruv Khullar spotlights how researchers from across MIT are using AI to advance drug development. Khullar highlights the MIT Jameel Clinic, the Broad Institute and various faculty members for their efforts in bridging the gap between AI and drug research. “With AI, we’re getting that much more efficient at finding molecules—and in some cases creating them,” says Prof. James Collins. “The cost of the search is going down. Now we really don’t have an excuse.”
Prof. Regina Barzilay joins BBC host Caroline Steel and other AI experts to discuss her inspiration for applying AI technologies to help improve medicine and fight cancer. “I think that in cancer and in many other diseases, the big question is always, how do you deal with uncertainty? It's all the matter of predictions," says Barzilay. "Unfortunately, today, we rely on humans who don't have this capacity to make predictions. As a result, many times people get wrong treatments or they are diagnosed much later.”
Writing for Forbes, lecturer Guadalupe Hayes-Mota '08, SM '16, MBA '16 explores the role of artificial intelligence and biotechnology in transforming the healthcare industry specifically for venture capitalists (VCs). “The fusion of AI and biotechnology presents a wealth of opportunities for venture capitalists,” writes Hayes-Mota. “By staying attuned to emerging trends and adopting strategies for impactful investments, VCs can drive innovation and create transformative changes in healthcare.”
Prof. Regina Barzilay spoke at The Futurist Summit: The Age of AI – an event hosted by The Washington Post – about the influence of AI in medicine. “When we're thinking today how many years it takes to bring new technologies [to market], sometimes it's decades if we’re thinking about drugs, and very, very slow,” Barzilay explains. “With AI technologies, you've seen how fast the technology that you're using today is changing.”
Prof. Bob Langer and Prof. Giovanni Traverso have co-founded Syntis Bio, a biotech company that will use technology to “coat the stomach and potentially other organ surfaces, [change] the way that drugs are absorbed or, in the case of obesity, which hormones are triggered,” reports Allison DeAngelis for STAT.
Prof. Regina Barzilay joins The Economist’s “Babbage” podcast to discuss how artificial intelligence could enable health care providers to understand and treat diseases in new ways. Host Alok Jha notes that Barzilay is determined to “overcome those challenges that are standing in the way of getting AI models to become useful in health care.” Barzilay explains: “I think we really need to change our mindset and think how we can solve the many problems for which human experts were unable to find a way forward.”
MIT have developed a new ingestible vibrating capsule that could potentially be used to aid weight loss, writes Newsweek’s Robyn White. Prof. Giovanni Traverso said the capsule “could facilitate a paradigm shift in potential therapeutic options for obesity and other diseases affected by late stomach fullness.”
MIT engineers have developed a new adhesive, low-cost hydrogel that can stop fibrosis often experienced by people with pacemakers and other medical devices, reports for Maria Bolevich Interesting Engineering. “These findings may offer a promising strategy for long-term anti-fibrotic implant–tissue interfaces,” explains Prof. Xuanhe Zhao.
In an article for Fast Company, Lecturer Guadalupe Hayes-Mota offers five takeaways concerning the potential impact of AI on healthcare. Understanding AI’s healthcare potential “is crucial for business leaders and policymakers to foster an environment where AI and other analytics tools enhance rather than complicate societal outcomes,” Hayes-Mota writes.
Writing for STAT, Prof. Kevin Esvelt explores how, “the immense potential benefits of biotechnology are profoundly vulnerable to misuse. A pandemic caused by a virus made from synthetic DNA — or even a lesser instance of synthetic bioterrorism — would not only generate a public health crisis but also trigger crippling restrictions on research.” Esvelt adds: “The world has too much to gain from the life sciences to continue letting just anyone obtain DNA sufficient to cause a pandemic.”
Prof. Giovanni Traverso and colleagues have developed a new ingestible sensor that could be used to help diagnose gastrointestinal conditions, reports Jeremy Hsu for New Scientist. “Eventually, the futuristic device could provide treatments for gut illnesses through electrical stimulation via additional electrodes embedded in the sensor,” Hsu notes.